

# OLIVIER J.WOUTERS PH.D.

London School of Economics Cowdray House 2.06 London WC2A 2AE  
o.j.wouters@lse.ac.uk +44 2078523570

## EMPLOYMENT

---

2019 Assistant Professor of Health Policy  
Director, M.Sc. Global Health Policy  
Department of Health Policy  
London School of Economics and Political Science

2018-2019 Fellow in Health Economics

- 201920      Affiliated Faculty Member, Leuven Institute for Healthcare Policy, KU Leuven, Belgium
- 201518      Visiting Research Fellow, Health Economics Unit, University of Cape Town, South Africa

GRANTS

---

- 2023      Co-principal investigator, grant from the Commonwealth Fund to study US pricing reforms under the Inflation Reduction Act of 2022 (\$248,656)
- 2021      Principal investigator, internal grant from LSE Research Support Fund to conduct global study of drug price affordability, and availability (£20,000)

SHORT-TERM CONSULTANCIES

---

- 202425      World Bank
- 2023      World Health Organization Regional Office for Europe
- 2019      African Development Bank
- 2013-17      World Bank
- 2014      World Health Organization
- 2014      Organization for Economic Cooperation and Development
- 2013      Ministry of Health of Greece
- 2011      Research Triangle Institute International

PUBLICATIONS

---

PEER-REVIEWED ARTICLES

- Wouters OJ, Vogel M, Feldman WB, Beall RF, Kesselheim AS, Tu SS (2024) Potential legal protections for biologics vs small molecule drugs in the US' *JAMA* (in press).
- Wouters OJ, Kuha J (2024) Low- and middle-income countries experienced delays accessing new essential medicines, 1982-2024. *Health Affairs* (in press).
- Wouters OJ, Naci H, Papanicolas I (2024) [Availability and coverage of new drugs in 6 high income countries with health technology assessment bodies](#). *Internal Medicine*, 184(3): 323-330. [Reply](#) *JAMA Internal Medicine*, 2024; 184(7): 851.

Wouters OJ, Kesselheim AS, Kuha J, Luyten J (2024).





Wouters OJ (2024). ["Lobbying in US health care lessons from the field of oncology"](#) *Journal of the National Comprehensive Cancer Network*, 22(4): 272-276.

Hernandez M, Wouters OJ, Cousin EM, Kirihenedige AS, Sullivan SD (2024). ["Interpreting the first round of maximum fair prices negotiated by Medicare for drugs"](#). *Affairs Forefront*. <https://10.1377/forefront.20240830.863408>

Van Schalkwyk MCI, Jarman H, Hervey T, Wouters OJ, Barlow P, McKee M (2020). ["Risks to health and the NHS in the post-Brexit era."](#) *BMJ*, 369: m2307.

Wouters OJ, Hervey T, McKee M (2020). ["Brexit and the European Medicines Agency: What next for the agency and UK drug regulators?"](#) *JAMA Health Forum*, 1(2): e200135.

Luyten J, McKee M, Wouters OJ (2020). ["How much does it cost to research and develop a new medicine?"](#) [in Dutch]. *Nederlands Tijdschrift voor Geneeskunde*.

Wouters OJ, McKee M (2017). ["Private financing of health care in times of economic crisis: A review of the evidence."](#)

Laviolette L, Gopalan S, Elder L, Wouters OJ (2016). [Incentivizing nutrition: How to apply incentive mechanisms to accelerate improved nutrition outcomes compendium](#). The World Bank, Washington, DC p.

Pantelli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E, Gerkens S, Henschke C, Hislop J, Jommi C, Kaitelidou D, Kawalec P, Keskimäki I, Kroneman M, Lopez Bastida J, Pita Barros P, Ramsberg J, Schneider P, Spillane S, Vogler S, Vuorenkoski K, Vanhoes H, Wouters O, Busse R (2016). [Pharmaceutical regulation in 15 European countries: Review](#). *Health Systems in Transition*, 18(5): 118.

Cylus J, Wouters OJ, Kanavos P (2015). [Chapter 9. Understanding the role of governance in the pharmaceutical sector: From laboratory to patient](#). Greer S, Wismar M, Figueras J (eds.) *Strengthening Health System Governance: Better Policies, Stronger Performance*. European Observatory on Health Systems and Policies. Open University Press: Maidenhead, UK. pp. 175.

Kanavos P, Wouters OJ (2014). [Pharmaceutical policies in Cyprus: A review of the current system and future options](#).





The Economist. [The National Health Service has a new drugs plan](#), 23 November 2023 (Quoted).

Politico. \_\_\_\_\_, 25 April 2023 (Research referenced and quoted).

STAT News. \_\_\_\_\_, 16 March 2023 (Research referenced).

STAT News.

The Lancet Respiratory Medicine [Ensuring fair distribution of COVID-19 vaccines: is an](#)



Lars Van Cutsem (2023, visiting PhD student, KU Leuven, Belgium)

#### International Advisory Roles

Member, International Advisory Board, MSc Global Health, KU Leuven, Belgium (2023 present)

#### LANGUAGE & IT SKILLS

---

Languages: **English(native)**, **French(intermediate)**, and **Swedish(native)**

Computer Languages and Software: **LaTeX**, **NVivo**, **Python (basic)**, **R (basic)**, **Stata** and **TreeAge**

#### PROFESSIONAL SERVICE

---

##### Recognitions

[Distinguished Reviewer](#), JAMA Internal Medicine (2021 present)  
Top-graded peer reviewer, Annals of Internal Medicine (2016, 2018, 2020)  
Top-graded peer reviewer, JAMA (2023)  
Top-graded peer reviewer, JAMA Internal Medicine (2023)

##### Editorial Positions

Guest Academic Editor, PLOS ONE (2020, 2021)  
Guest Editor (with Panos G. Kanavos), Global Policy (2017)

Health Policy and Technology  
Inquiry  
International Journal of Clinical Practice  
International Journal of Health Policy and Management  
International Journal of Health Services  
JAMA  
JAMA Dermatology  
JAMA Health Forum  
JAMA Internal Medicine  
JAMA Network Open  
Journal of Acquired Immune Deficiency Syndromes  
Journal of Development Studies  
Journal of Globalization and Development  
Journal of the Royal Society of Medicine  
The Lancet  
The Lancet Public Health  
The Lancet Regional Health Europe  
The Lancet Regional Health Western Pacific  
The Milbank Quarterly  
Nature Communications  
Nephrology  
Open Heart  
PLOS Medicine  
PLOS ONE  
PNAS Nexus  
Saudi Pharmaceutical Journal  
Social Science & Medicine  
Vaccine  
Value in Health  
Value in Health Regional Issues  
World Medical & Health Policy

#### Grant Reviewer

Economic and Social Research Council (United Kingdom Research and Innovation)  
Swiss National Science Foundation

#### Professional Membership

Higher Education Academy (Fellow)  
International Society for Pharmacoeconomics and Outcomes Research

LAST UPDATED: September 2024